TFAP2C and prostate carcinoma: It has been found that SLC7A11 is involved in the development of resistance to docetaxel in prostate cancer, and the transcription factor AP-2γ (TFAP2C) inhibits ferroptosis in prostate cancer through the c-Myc/miR-25-3p/SLC7A11 signaling axis, which in turn promotes its resistance to chemotherapy [37,38].